A Pocket on the Surface of the N-Terminal BRCT Domain of Mcph1 Is Required to Prevent Abnormal Chromosome Condensation by Richards, MW et al.
A pocket on the surface of the N-terminal BRCT domain of Mcph1
is required to prevent abnormal chromosome condensation
Mark W. Richards1, Justin W.C. Leung2, S. Mark Roe1, Junjie Chen2, and Richard Bayliss1,*
1Section of Structural Biology, Institute of Cancer Research, Chester Beatty Laboratories, 237
Fulham Road, London, SW3 6JB, UK.
2Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer
Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.
Abstract
Mcph1 is mutated in autosomal recessive primary microcephaly and premature chromosome
condensation (PCC) syndrome. Increased chromosome condensation is a common feature of cells
isolated from patients afflicted with either disease. Normal cells depleted of Mcph1 also exhibit a
PCC phenotype. Human Mcph1 contains three BRCA1-Carboxyl Terminal (BRCT) domains, the
first of which (Mcph1N) is necessary for the prevention of PCC. The only known disease-associated
missense mutation in Mcph1 resides in this domain (T27R). We have determined the X-ray crystal
structure of human Mcph1N to 1.6Å resolution. Compared with other BRCT domain structures, the
most striking differences are an elongated, ordered β1-α1 loop and an adjacent hydrophobic pocket.
This pocket is in the equivalent structural position to the phosphate binding site of BRCT domains
that recognize phospho-proteins, although the phosphate-binding residues are absent in Mcph1N.
Mutations in the pocket abrogate the ability of full-length Mcph1 to rescue the PCC phenotype of
Mcph1−/− mouse embryonic fibroblast cells, suggesting that it forms an essential part of a protein-
protein interaction site necessary to prevent PCC.
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The Microcephalin/Mcph1/BRIT1 gene is mutated in autosomal recessive primary
microcephaly (MCPH) and premature chromosome condensation (PCC) syndrome 1; 2. These
diseases share characteristic symptoms of below average head diameter, reduced mental
capabilities and a cellular phenotype of chromosome condensation in the G2 phase of the cell
cycle. Disease-associated mutations in the Mcph1 gene have been identified that truncate the
protein (S25X, 427insA) or that produce a missense mutation (T27R) 1; 3; 4. Mcph1 expression
is reduced in cell lines derived from breast cancers, leading to the suggesting that it may
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function as a tumour suppressor gene 5. Mcph1 has been linked with DNA damage regulation,
repression of gene expression, cell-cycle progression and chromosome condensation, although
the precise function of the protein in these processes is not yet clear 5; 6; 7; 8; 9. Consistent
with these functions, Mcph1 normally localises to the centrosome and relocates to sites of DNA
repair after cells are exposed to ionizing radiation 5. Mcph1 contains three BRCA1-Carboxyl
Terminal (BRCT) domains: a single domain at the N-terminus and a tandem pair at the C-
terminus. BRCT domains function as protein-protein interaction modules, and tandem BRCT
domains act as phospho-peptide binding modules 10; 11. It is reasonable to predict that protein-
protein interactions mediated by the BRCT domains of Mcph1 make important contributions
to the functions of Mcph1. The interaction of the tandem BRCT domains of Mcph1 with γ-
H2AX is crucial for localization to sites of DNA damage after ionizing radiation 12. Mcph1
is recruited early in the DNA repair process, and its depletion disrupts the accumulation of
downstream factors. The N-terminal BRCT domain is necessary for prevention of PCC, and
contributes to the centrosomal localization of Mcph1, although binding partners for this domain
have remained elusive 13; 14.
The structures of several BRCT domains have been reported, including those present in the
DNA repair proteins XRCC1 and the tandem domain pair of BRCA1 bound to a phospho-
peptide 15; 16; 17. Despite very low sequence homology, the secondary and tertiary structures
of these domains are highly similar, consisting of a central four-stranded parallel β-sheet
enclosed by three α-helices 15. In tandem domains, the phospho-peptide binding site lies at the
interface of the two domains, with the residues that recognize the phosphate group on the first
domain in the β1-α1 loop and on the N-terminus of α2 16; 17; 18; 19; 20.
To gain insights into the function of the N-terminal BRCT domain of Mcph1 we determined
the X-ray crystal structure of this domain. The domain exhibits a hydrophobic pocket at the
equivalent position to the typical phosphate binding site. We show that this pocket is crucial
for the rescue of abnormal chromosome condensation in cells lacking wild-type microcephalin.
Human Mcph1 is an 835 amino acid protein that comprises three BRCT domains but no other
recognizable domains (Figure 1a). We produced and crystallized a fragment of Mcph1
(Mcph1N) that encompasses the first BRCT domain comprising the first 95 amino acids of
Mcph1. Molecular replacement failed with known BRCT domain structures, and as yet no
novel individual BRCT domains have been solved using this method. The structure of Mcph1N
was solved to 1.6Å by Single wavelength Anomalous Diffraction (SAD) phasing using protein
crystals incorporating selenomethionine. The asymmetric unit comprises four copies of
Mcph1N two of which extend the full 95 amino acids (chains A and B), and the other two lack
the first three amino acids (chains C and D). The refinement and geometry statistics, and the
final 2mFo-DFc electron density map are consistent with a high resolution, high quality
structure (Table 1, Figure 1b).
DALI was used to identify the most similar BRCT domain structures and to produce the
structure-based sequence alignment (Figure 1c 21). The sequence identity between Mcph1N
and the other BRCT domains is in the range 9 – 20%, and no residues are identical in all nine
proteins. These domains are more highly conserved at the secondary and tertiary structure level
(DALI RMSD, root mean square deviation, 1.7 – 3.4 Å). The only structural feature of Mcph1N
for which a match was not found among other BRCT domains is the extended loop between
β1 and α1, which protrudes an additional ~8Å in Mcph1 when compared to XRCC1 (Figure
1d). This loop is held in an ordered conformation by H-bonds between the mainchain and the
sidechains of Ser17 and Asn19 (Figure 1e).
To identify potential surface features that might play a role in the function of this domain, we
analyzed the conservation of Mcph1N homologues. Mcph1N is well conserved among
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vertebrates and many of the conserved residues are in the four β-strands that are buried in the
interior of the protein (Figure 2a). The surfaces of the protein, including the outsides of the
four helices, are mostly not conserved, although there is a striking surface patch of conserved
residues formed by β1, the β1-α1 loop and α1 (Figure 2b). This patch abuts the site of the
microcephaly mutation Thr27, which suggested to us that it might be of functional relevance.
We therefore included residues from this region in our functional analysis, as described below.
Inspection of the crystal packing contacts revealed a surface pocket composed of Trp16 and
Tyr56 that was involved with two different contacts (Figure 2c). In one type of crystal contact,
the sidechain of Lys45 of chain C or chain D packs into the pocket of chain A or chain B
respectively. In the other type of crystal contact, the sidechain of Met1 of chain A or chain B
packs against the pocket of chain C or chain D respectively. In the first domain of tandem
BRCT domains, the equivalent region forms the phosphate-binding pocket in the phospho-
peptide binding site, as shown for BRCA1 in the left panel of Figure 2d 19. In Mcph1N this
region is incompatible with phosphate binding because the crucial phosphate-binding residues
(i.e. Lys1702, Ser1655 using BRCA1 numbering) are replaced by Thr59 and Glu14 (Figure
2d, centre panel). In addition, the surface of Mcph1N in and around this pocket is acidic rather
than basic (Figure 2d, right panel). The tryptophan sidechain is conserved in vertebrates and
the tyrosine is less well conserved (Figure 2a), although the substitutions could conserve the
hydrophobic nature of the pocket. The fact that this unusual surface feature of Mcph1N
occupies the position of the phospho-binding pocket in other BRCT domains suggested to us
that it might be involved in protein-protein interactions, and that this site should be included
in our functional analysis.
In a population of mouse embryonic fibroblasts (MEFs) prepared from Mcph1−/− knockout
mice, approximately 30% of the cells exhibit PCC, which recapitulates the defect observed in
cells derived from microcephaly or PCC syndrome patients 14. The introduction of wild-type
Mcph1 in these Mcph1−/− MEFs reduces the proportion of cells that exhibit PCC to 2–3%,
which is similar to that observed in wild-type MEFs. 40–50% of the Mcph1−/− MEFs also have
abnormally condensed chromosomes during metaphase, which can be rescued by the
expression of wild-type Mcph1, but not by a mutant lacking the Mcph1N domain 14. The
Mcph1N domain is therefore crucial for the function of Mcph1 in prevention of abnormal
chromosome condensation, and we decided to identify essential residues for this function
within Mcph1N. Based on the above structural analysis, we designed several mutations in full-
length Mcph1 and tested their abilities to rescue abnormally condensed metaphase
chromosomes in Mcph1−/− MEFs. We made Y24A and K53A to disrupt the conserved surface
patch (Figure 2b), W16A and Y56S to disrupt the pocket (Figure 2c) and the T27R mutation
that was found in a microcephaly patient 4. The position of these mutations within the Mcph1N
structure is shown in Figure 3a. Metaphase spreads were prepared from Mcph1−/− MEFs
expressing Mcph1 and the proportion of cells exhibiting abnormally condensed chromosomes
were counted (Figure 3b, c). As previously observed, fewer than 10% of wild-type MEFs
displayed abnormally condensed chromosomes, whereas almost 50% of the Mcph1−/− MEFs
had abnormally condensed chromosomes. Mcph1 containing mutations in the conserved
surface patch was able to rescue this metaphase chromosome condensation defect to an extent
similar to wild-type Mcph1, ruling out a critical role for this patch in this chromosome
condensation function of Mcph1. The T27R mutant of Mcph1 was only slightly impaired in
this function, consistent with the previous report that this patient’s cells only shows mild PCC
phenotype. In contrast, the pocket mutations were significantly reduced in their abilities to
rescue this chromosome condensation defect, with almost 30% of cells expressing the W16A
mutant of Mcph1 exhibiting abnormally condensed chromosomes. This is very similar to the
proportion previously observed with a fragment of Mcph1 lacking the entire Mcph1N domain
14, and therefore the W16A mutation recapitulates the effect of the loss of the domain with
respect to chromosome condensation. None of the mutations compromised the ability of Mcph1
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to relocate to γ-H2AX foci upon irradiation (Figure 3d), consistent with the previous report
that the C-terminal BRCT domains are required for Mcph1 localization to sites of DNA breaks
12. We used circular dichroism spectroscopy and a thermal shift assay to show that neither
pocket mutations nor the T27R microcephaly mutation disrupt the fold of the Mcph1N domain
or reduce its thermal stability (Figure 3e,f). Based on these observations, we conclude that the
pocket is a crucial feature required for Mcph1 function in the regulation of chromosome
condensation.
The phosphate-binding pocket is a conserved feature of the first domain of tandem BRCT
repeats and the equivalent site was postulated to be a site of protein-protein interaction on the
C-terminal BRCT domain of XRCC1 15; 16; 17; 18; 19; 20. We have now shown that the
equivalent surface on the N-terminal BRCT domain of Mcph1, on the β1-α1 loop and the N-
terminus of α2, is a functionally important site for Mcph1 function in prevention of abnormal
metaphase chromosome condensation. This region of the BRCT domain is the most divergent
structurally from other BRCT domains, due to the more elongated β1-α1 loop and the presence
of a pair of surface aromatic sidechains. This pocket is presumably a crucial element of the
interface of a protein-protein interaction. Future work will identify the binding partners of
Mcph1 that mediate its function in prevention of PCC, and define the structural basis of their
interactions.
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Figure 1. X-ray crystal structure of the first BRCT domain of Mcph1
(a) The domain structure of Mcph1. The N-terminal BRCT domain (Mcph1N) is shown as a
green box, the C-terminal tandem BRCT domains (Mcph1C) are shown as black boxes. (b) A
stereo diagram showing a representative region of the refined structure and 2mFo-DFc electron
density contoured at 1.0σ. All structure figures were made using PyMOL 25. (c) The secondary
structure assignment of Mcph1N is shown above a structure-based sequence alignment of its
closest structural homologues. Abbreviated names of structural homologues are shown on the
left: XRCC1C - XRCC1 C-terminal domain (1cdz chain A15); RNApII - RNA polymerase II
(3ef1 chain A26); 53BP1 - 53BP1 second domain of tandem (1gzh chain D27, 1kzy chain
D28) ; MDC1 – MDC1 second domain of tandem (2ado chain A29, 2azm chain A 19); BRCA1
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- BRCA1 second domain of tandem (1jnx chain X 30) ; ECT2 - ECT2 C-terminal domain
(2cou); XRCC1N - XRCC1 N-terminal domain (2d8m); DNAIVN - DNA ligase IV N-terminal
domain (2e2w), The residue numbering is taken from the coordinate files. (d) A cartoon
representation of the superposition of Mcph1N (green) with XRCC1C (red). The secondary
structure elements and the first and last residues of Mcph1N are labeled. (e) A magnified view
of the β1-α1 loop region of Mcph1N. The putative H-bonds between sidechain residues and
the mainchain are shown as dashed lines.
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Figure 2. Identification of potential functional sites on the surface of Mcph1N
(a) The sequence conservation among vertebrate Mcph1 homologues is shown using the color
scheme: red for identical; magenta for conserved, grouped by (ILVM), (YF), (DE), (RK), (ST);
white for non-conserved. The sequence alignment was made using ClustalW 31. (b) Sequence
conservation as defined in (a) mapped onto the surface of Mcph1N. The microcephaly mutation
T27R and residues that form a conserved surface patch are marked. (c) The two different crystal
contacts that involve the surface pocket formed by Trp16 and Tyr56 are shown using a cartoon
representation of the protein mainchain and a stick representation of the interacting sidechains.
The colour scheme used is: chain A green, chain B yellow, chain C magenta, chain D cyan.
(d) The left panel shows the binding of phospho-peptide (grey carbon atoms) to the first domain
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of BRCA1 BRCT tandem pair (orange cartoon and carbon atoms) 19. The central panel shows
the equivalent region of Mcph1N in the same view. The right panel shows the electrostatic
potential (colour ramped from red=negative to blue=positive, calculated using PyMOL) of the
Mcph1N surface in a view rotated by ~90°.
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Figure 3. Pocket mutations do not rescue the abnormal chromosome condensation phenotype of
Mcph1−/− cells
(a) The position of residues mutated in this study on the structure of Mcph1N. (b,c) Rescue of
premature chromosome condensation (PCC) phenotype of Mcph1−/− MEFs by wild-type (WT)
or mutant Mcph1. (b) Shows the quantification of metaphase cells with condensed
chromosomes observed in each indicated cell line. (c) Shows examples of metaphase spreads
seen in these cell lines. (d) Proper localisation of wild-type and mutant Mcph1 to γ-H2AX foci
upon ionizing radiation (IR). Cell culture, transfection, chromosome spreads, irradiation and
immunofluorescence were carried out as described in 14. (e) Circular dichroism spectroscopy
shows that the WT, T27R, W16A and Y56S Mcph1N domain proteins are folded. Spectra were
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collected using 1 mg/ml samples in 10mM sodium phosphate pH 7.5, 20 mM sodium chloride
in a 0.01 cm pathlength quartz cell at 18 °C on an Aviv 202SF instrument (Aviv Biomedical).
Data were processed using CDTool software 32. (f) A thermal shift assay shows that the T27R,
W16A and Y56S Mcph1N domain proteins are at least as thermally stable as the WT domain
protein. The thermal shift assay is based on the increased fluorescence of a dye upon binding
to the exposed hydrophobic core of proteins unfolded by a temperature gradient 33. 25 ml
samples containing 0.3 mg/ml protein and 5x Sypro Orange dye (Sigma) in 10 mM sodium
phosphate pH 7.5, 20 mM sodium chloride were heated from 4–95 °C at 2 °C/min in a BioRad
IQ5 instrument and monitored at excitation and emission wavelengths of 485 nm and 585 nm.
The mean of eight denaturation curves was calculated for each protein and the buffer alone;
the baseline was then subtracted. Data were fitted to a Boltzmann sigmoid function to yield
temperatures of 50% denaturation (apparent Tm) of 52.6 °C (WT), 52.7 °C (T27R), 55.1°C
(W16A), 59.5 °C (Y56S).
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Table 1
Summary of crystallographic analysis
His6-tagged Mcph1N protein was expressed in B834 cells co-transformed with the CodonPlus RIL plasmid grown
in SelenoMet Medium (Molecular Dimensions). The protein was purified using a 5ml chelating Sepharose
column (GE Healthcare) that had been charged with nickel and equilibrated with 100 mM sodium phosphate pH
7.5, 0.5 M NaCl. The column was washed with 50 mM imidazole and eluted on a gradient 50–500 mM imidazole
in this buffer. The eluted protein was cleaved using His-tagged TEV protease for 3 hours at 21°C. The cleaved
protein was passed through a second nickel column to remove the tag and protease. The protein was dialysed
into 20 mM sodium phosphate pH 6.0, 1 mM EDTA, 50 mM sodium chloride and applied to a SP Sepharose
column (GE Healthcare). The protein was eluted on a gradient 50–750 mM sodium chloride in this buffer. The
eluted protein was further purified by gel filtration on a Superdex 75 16/60 column equilibrated in 20 mM Tris-
HCl pH 7.5, 80 mM NaCl. Crystals were grown at 18 °C using the hanging-drop vapour diffusion method using
100 mM MES pH 6.0, 18% PEG 6000, 200 mM ammonium chloride in the reservoir. 2 µl of 15 mg/ml protein
stock was mixed with 2 µl of reservoir solution to form the drop and then microseeded. Crystals were flash-
frozen in reservoir solution supplemented with 20% glycerol. X-ray diffraction data was processed using CCP4
software 22. The structure of Mcph1N was solved using Phenix 23 to locate the selenium sites, automatically
build the four protein chains and for refinement. Manual rebuilding was carried out using Coot 24.
Crystals
Spacegroup P21
Lattice constants a (Å) 80.98
b (Å) 34.21
c (Å) 84.24
β (°) 113.53
Data collection
X-ray source Diamond I03
Wavelength (Å) 0.92
Resolution range (Å) 45.3-1.6
(Highest resolution shell) (1.69-1.60)
Unique reflections 56453 (8180)
Completeness(%) 99.7 (99.9)
Multiplicity 4.3 (3.6)
Rmerge (%) 5.2 (33.6)
I/σ(I) 16.1 (3.2)
Refinement
Resolution range (Å) 45.3-1.6
Number of:   amino acids 377
  waters 469
Rfactor (%) 19.02
Rfreea (%) 22.21
Bond deviation (Å) 0.007
Angle deviation (°) 1.057
Molprobity output scores
All-atom Clashscore 8.15
Bad rotamers (%) 2.5
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Ramachandran outliers (%) 0.0
Ramachandran favoured (%) 98.6
a
Free Rfactor was computed using 5% of the data assigned randomly 30.
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